CEO Jan Mikkelsen highlighted 2024 as a pivotal year, with SKYTROFA achieving €200 million in revenue and a 6.5% share of the U.S. growth hormone market. The product now holds 45% of the U.S.

Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million– Following ...

Reports Q4 revenue EUR 173.92M vs. EUR 137.7M last year. “Having achieved pivotal milestones in 2024, Ascendis is positioned to continue strong ...

Pepto-Bismol (bismuth salicylate) and Tums (calcium carbonate) are both over-the-counter (OTC) medications for heartburn and ...

Drawing from personal experience, Patty Keating advocates for greater awareness, improved diagnosis, and treatment among ...

Cantor Fitzgerald reaffirmed its Overweight rating and $170.00 price target on Ascendis Pharma (NASDAQ:ASND) shares, currently trading at $119.49. The firm's analyst highlighted the early adoption of ...

News, weather, traffic and more from FOX 5, serving the District of Columbia, Maryland and Virginia. Super Bowl commercials ...